Gossamer Bio Stock Surges on Positive FDA Update, Reacquisition of Seralutinib Rights

Shares of Gossamer Bio (NASDAQ: GOSS) surged by as much as 37.7% in pre-market trading Monday following a series of significant updates that clarified the regulatory path and commercial potential for its lead drug candidate, seralutinib.

FDA Submission Pathway Confirmed

The centerpiece of the company's announcement was confirmation of a productive Pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration. Gossamer stated that based on the official minutes from the meeting, it is on track to submit an NDA for seralutinib in pulmonary arterial hypertension (PAH) in September 2026.

If the FDA accepts the filing for review, a potential approval decision could be made in the third quarter of 2027. This development provides investors with a clear timeline and significantly de-risks the regulatory process for the company's most important asset.

Full Commercial Rights Reacquired

Ad

In a key strategic move, Gossamer announced it has reacquired full worldwide development and commercial rights to seralutinib by mutually terminating its collaboration agreement with Chiesi. The terms of the termination are notably favorable for Gossamer, which made no upfront cash payment to regain the asset.

Instead, Chiesi will pay Gossamer a one-time settlement of $5 million. Chiesi will retain a capped royalty on future net sales, leaving Gossamer with the substantial majority of the drug's potential global revenue. This allows the company to capture the full upside of a potential first-in-class PAH therapy.

Corporate and Financial Updates

Gossamer also reported several actions to stabilize its balance sheet. Stockholders approved proposals tied to a convertible note exchange and authorized a reverse stock split. The company also disclosed a preliminary second-quarter cash position of approximately $57 million.